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Introduction: Rapid functional assays have been proposed to overcome the limitations of washed platelet assays in 
the work-up of patients with suspected heparin-induced thrombocytopenia (HIT). Data on the diagnostic accu-
racy are, however, scarce and conflicting. We aimed to study the diagnostic accuracy of a rapid, flow cytometer- 
based assay and to explore sources of variability. 
Material and methods: Frozen serum samples of 103 consecutive patients, evaluated for suspected HIT at our 
institution in 2017, and characterized with 4Ts score, IgG-PF4/heparin ELISA (GTI), HemosIL®Acustar (IgG), as 
well as heparin-induced platelet activation test (HIPA), were further tested using HIT Confirm, determining P- 
selectin release of donor platelets after incubation with patient’s serum. The diagnosis of HIT was defined as a 
positive HIPA result. 
Results: HIT was confirmed in 15 out of 103 patients corresponding to a prevalence of 14.6%. HIT Confirm was 
positive in 11 patients (10.7%), negative in 88 patients (85.4%), and inconclusive in 4 patients (3.9%). According 
to the intention-to-diagnose principle, the number of true positives was 9, the number of true negatives 83, the 
number of false negatives was 6, the number of false positives 5. This corresponds to a sensitivity of 60.0%, and a 
specificity of 94.3%. Modifications of the test did not improve sensitivity. 
Conclusions: The rapid, flow cytometer-based assay HIT Confirm is able to verify HIT in positive patient samples 
but cannot rule-out HIT in clinical practice. Other rapid functional assays shall be studies in appropriately 
designed diagnostic accuracy studies.   
1. Introduction 
Because of the complex mechanism of heparin-induced thrombocy-
topenia (HIT), the diagnostic work-up is challenging. HIT is an immu-
nological disorder caused by the development of antibodies that 
recognize platelets factor 4 (PF4) complexed with polyanions such as 
heparin (anti-PF4/ H abs). These immune complexes bind to FcγIIA- 
receptors, trigger activation of platelets, support derivation of platelet 
microparticles, and, subsequently, accelerate thrombin generation [1]. 
Well-known clinical consequences are thrombocytopenia and massive 
thromboembolism. Immunoassays such as enzyme-linked immunosor-
bent assay (ELISA) or chemiluminescence immunoassay (CLIA) [2] can 
quantify anti-PF4/H antibodies with high sensitivity [3]. However, 
immunoassays cannot distinguish antibodies that activate platelets and 
others that do not [4–6]. Besides, the diagnostic accuracy depends on 
the type of the antibody, diagnostic thresholds, and manufacturers [7]. 
Thus, functional assays are needed to demonstrate anti-PF4/H anti-
bodies’ capability to activate platelets [1]. 
Functional assays demonstrate the activation of donor platelets in 
the presence of anti-PF4/H antibodies and heparin [4,8–11]. Donors’ 
platelets are stimulated either in whole blood (WB), platelet-rich plasma 
(PRP), or after washed platelets (WP) [10]. Washed platelet assays, the 
serotonin release assay (SRA) [12], and the heparin-induced activation 
test (HIPA) [9], are regarded as reference (gold) standard [13] to di-
agnose HIT. They appear sensitive and specific because the test does not 
utilize donors’ PRP, affecting the reaction [3]. However, these tests are 
expensive, time-consuming, and required a particular laboratory infra-
structure [3]. Rapid functional tests overcoming these shortcomings 
have been developed, but the diagnostic accuracy is still an open issue. 
Examples include heparin-induced platelet aggregometry (PAT) [14], 
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and multiple electrode platelets aggregometry (Multiplate®) [15]. Even 
though some agreement with washed platelet assays were observed, the 
accuracy was clearly inferior in some cases [14]; others require further 
standardization and appropriate diagnostic accuracy studies [3]. 
Recently, the new cytometer-based test HIT Confirm® assessing the P- 
selectin (CD62P) release of donor platelets surface after incubation with 
patient’s serum was developed. Few evaluation studies are available, but 
the results are conflicting [16–18]. 
With the present study, we aimed to comprehensively assess the 
diagnostic accuracy of the rapid, flow cytometer-based functional assay 
HIT Confirm and to explore sources of variability. 
2. Material and methods 
2.1. Design, setting and population 
The present cross-sectional analysis was conducted in-line with a 
large prospective cohort study (TORADI-HIT). One-hundred and forty 
consecutive patients referred with suspected HIT to a specialized labo-
ratory of a University hospital in 2017 were screened. The flow of the 
patients is shown in Fig. 1. HIPA was conducted if not done in clinical 
practice; ELISA and AcuStar were additionally completed. Inclusion 
criteria were (1) referred with suspected HIT, (2) 4Ts score rated by the 
consultancy team (at least clinical characteristics available), (3) 
immunoassay test results available, (4) residual serum samples avail-
able, (5) age above 18 years, and (6) signed general informed consent. 
Inselspital University Hospital is a large tertiary hospital in Switzerland 
covering a catchment area of more than 1.5 million inhabitants. The 
appropriate ethical committee approved the protocol of the study. The 
study was conducted in accordance with the declaration of Helsinki. 
2.2. Collection, storage and handling of samples 
For practicability reasons, plasma samples were obtained to deter-
mine AcuStar HIT IgG and IgG ELISA, and serum samples to conduct HIT 
Confirm and HIPA. A standardized protocol was implemented to ensure 
adequate preanalytic conditions [14,19]. Samples were collected into 
3.2% sodium citrate (4.3 mL S-Monovette, Sarstedt Nümbrecht, Ger-
many) and serum (4.7 mL S-Monovette, Sarstedt Nümbrecht, Germany) 
containers. Platelet-poor plasma was obtained by double centrifugation 
at 1500 ×g for 10 min at room temperature; serum was centrifuged by 
3137 g for 7 min [20]. Samples were immediately snap-frozen at − 20 ◦C 
and stored at − 80 ◦C. AcuStar HIT IgG was conducted before freezing; 
ELISA and HIPA were conducted in batches every other day. 
Fig. 1. Design of the cross-sectional diagnostic accuracy study. Consecutive patients referred with suspected HIT were included, and Emo-Test HIT Confirm® 
conducted. Heparin-induced platelet aggregation test was used as the reference standard. HIPA, heparin-induced platelets assay; HIT, heparin-induced 
thrombocytopenia. 
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2.3. Collection of clinical data and determination of immunoassays 
Clinical characteristics were collected by the hematology consulta-
tion service, which is activated in every case a HIT antibody test is 
requested. In-line with this consultation, a 4Ts score is rated. For this 
analysis, these data were retrieved from the electronic patient docu-
mentation. HemosIL AcuStar HIT-IgG (Instrumentation Laboratory, 
Bedford, MA, USA) was conducted using citrated plasma samples 24/7 
as the time of suspected HIT on a BIO-FLASH1 analyzer (Inova Di-
agnostics, San Diego, California, USA). The determination was done 
according to the manufacturer’s instructions. An IgG-specific ELISA was 
conducted using plasma samples in batches every other day (Immunocor 
Lifecode PF4 IgG) according to the manufacturer’s instructions. 
2.4. Preparation of platelet-rich-plasma, (PRP) donor and patients’ 
samples 
Whole blood of five unselected healthy donors was collected into 
acid-citrate-dextrose solution (ACD) containers to prevent platelet ag-
gregation and bind residual calcium. The material was prepared within 
3 h after collection. PRP was prepared by centrifugation at 120 ×g for 20 
min without brake, at room temperature [9] after resting for 30 min. 
Patient samples were prepared by thawing for 5 min at 37 ◦C and heat- 
inactivated by 56 ◦C for 45 min. Then, samples were centrifuged by 
10,000 ×g for 5 min [14]. 
2.5. Determination of Emo-Test HIT Confirm® done on PRP 
The Emo-test HIT Confirm® assay (Emosis SAS, Illkirch- 
Graffenstaden, France) was performed according to the manufac-
turer’s instructions [10,16]. First, an initial mix was generated using 50 
μL donor PRP as well as 115 μL dilution buffer and labeled with 5 μL 
antibodies (CD41-PE and CD62P-FITC). Then, we incubated 35 μL of the 
mix, 10 μL of patient’s serum, and positive control material (activated 
with at thrombin receptor activating-peptide [TRAP]) and negative 
control material (dilution buffer) in the presence of heparin (0.3 IU/mL 
or 100 IU/mL respectively) in the dark. Following 30 min of incubation 
at room temperature, stimulation was stopped using 450 μL of dilution 
buffer. Samples were immediately analyzed by BD FACSCANTO™ II 
Flow Cytometer (BD Biosciences, San José, CA 95131 USA). CD41/CD62 
surface expression was measured. The percentage of CD62P+ platelets 
was measured for 3 IU and 100 IU heparin, respectively, by analyzing 
10′000 events of CD41+ platelets. The cutoff was defined at the inter-
section of the negative and positive control of the FITCCD62P histo-
gram. The percentage of CD62P positive events was defined as the 
platelets activation index (HEPLA): [(R% UFH 0.3 − R% UFH100)/ (R% 
positive control − R% negative control)] × 100. The cutoffs defined by 
the manufacturer were used (≥13%, positive result; ≥9.6% inconclusive 
results). 
2.6. Test modifications 
We hypothesized that various test modifications might improve the 
diagnostic performance of HIT Confirm: (1) use of washed platelets 
rather than PRP, (2) using platelets of a second donor, and (3) filtrating 
the patient’s serum. The number of experiments was restricted because 
of the limited amount of residual patients’ material. 
Nine patient samples with false-negative or inconclusive results in 
the HIT Confirm assay were selected and re-tested with washed platelets 
using various donors. The process of washing platelets is described 
below [4,8,14]. 
Eight patient samples with false-negative or inconclusive results in 
the HIT Confirm assay were re-tested with a second, independent 
platelet donor. 
Ten patient samples with false-negative or inconclusive results in the 
HIT Confirm were re-tested after filtration of patients’ serum. The 
filtration was done using a spin –X Centrifuge Tube filter cellulose ac-
etate of 0.22 μm (Costar®, Salt Lake City, USA). 
2.7. Determination of HIPA test 
HIPA test was performed as described previously [4,9,14,16]. Each 
serum sample was tested with four different washed platelets donor in 
the absence (buffer) and in the presence of different heparin concen-
trations (0.2 IU, 100 IU/mL) in a 96-microwells plate. PRP was prepared 
as mentioned above, and the platelets were washed as follows: the first 
pellet was re-suspended using calcium- and magnesium-free Tyrode’s 
buffer at pH 6.3 (adding glucose and apyrase); the second pellet was re- 
suspended using calcium- magnesium-containing Tyrode’s buffer at pH 
7.2, and the suspension was incubated at 37 ◦C for 45 min. After thawing 
(5 min at 37 ◦C) and heating to inactivate residual thrombin (45 min at 
56 ◦C), the patient’s samples were transferred to the microplate well, 
adding platelet suspension and buffer or heparin, respectively. The 
microplate was incubated on a magnetic stirrer plate with two steel balls 
per well approximately by 600 rpm. The plate was examined every 5 min 
against the light. A patient was interpreted as positive if an aggregation 
of the platelets at least in two donors occurs within 30 min in the 
presence of 0.2 IU/mL of heparin, but not in the presence of 100 IU/mL 
heparin. Interpreting time is 45 min, and each test plate included posi-
tive and negative control. 
2.8. Statistical analysis 
Descriptive statistics were used to characterize the study population 
and describe the distribution of test results (median and IQR/ ranges or 
frequencies as appropriate). Diagnostic accuracy of the Emo-test HIT 
Confirm® assay was determined by calculating the sensitivity, the 
specificity, and the likelihood ratio in relation to the presence of HIT 
(defined as a positive HIPA test). Following the intention-to-diagnose 
principle, we created 3 × 2 tables and counted inconclusive results as 
negative in HIT positive patients and positive in HIT negative patients 
[21]. A logistic regression analysis fitting a maximum-likelihood 
dichotomous model was performed to explore the extent to which HIT 
Confirm contributes to the diagnostic process. HIPA result was used as 
the dependent variable, ELISA results, and HIT Confirm as independent 
variables. Analyses were performed using the Stata 14.1 statistic soft-
ware package (StataCorp. 2014. Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP). 
3. Results 
3.1. Patient characteristics 
Out of 140 patients screened, 37 were excluded because of missing 
data, refused informed consent, or insufficient sample material (Fig. 1). 
The median age was 69 years (interquartile range [IQR] 60 to 76), 39% 
of the patients were female. The median 4 T’s score was 5 points in 
patients with HIT (IQR 3.5, 6), and 3 points in patients without HIT (IQR 
2, 4). The median IgG-specific ELISA was 3.0 in patients with HIT (OD; 
IQR 2.1, 3.3) and 0.2 in patients without HIT (0.15, 0.4). HIT was 
confirmed by a positive HIPA test in 15 patients (14.6%), a number that 
was higher than expected. Indeterminate results with the HIPA test were 
not observed. Detailed patient characteristics are given in Table 1. 
3.2. Diagnostic accuracy of HIT confirm 
The distribution of HIT Confirm test results in HIT positive and HIT 
negative patients is illustrated in Fig. 2 (panel A). Among the 15 patients 
with confirmed HIT, nine samples tested positive with HIT Confirm (% 
HEPLA >13), resulting in a true positive rate (sensitivity) of 60% (95% 
confidence interval [CI] 32.3, 83.7). HIT Confirm tested negative in five 
patients (%HEPLA <9.6), and the result was inconclusive in one patient 
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(%HEPLA 9.6 to 13.0). Among HIPA negative patients, two tested pos-
itive for HIT Confirm, and three were inconclusive. The specificity was 
thus 94.3% (95% CI 87.2, 98.1). The results are illustrated in Fig. 2 
(panel B). 
We further analyzed the diagnostic accuracy of HIT Confirm within 
different risk categories of the 4Ts score. In patients at low risk, the 
sensitivity was 0% (95% CI 0% to 71%) and the specificity 98% (89, 
100). At intermediate risk, the sensitivity was 50% (7, 93), and the 
specificity was 97 (85, 100). At high risk, the sensitivity was 88% (47, 
100), and the specificity was 100% (40, 100). 
To contrast the accuracy of HIT confirm with ELISA’s accuracy, we 
calculated the sensitivity of ELISA IgG in our dataset (100%, 95%CI 75, 
100), and the specificity (77% 95%CI 66, 85). The numbers of true 
positives, false negatives, false positives, and true negatives were 13, 0, 
20, and 66. 
To explore how HIT confirm contributes to the diagnostic process, 
we conducted a logistic regression analysis. Whereas the odds ratio was 
23.1 for ELISA (95% CI 3.3, 165.2), it was 1.2 for HIT Confirm (95%CI 
0.9, 1.6; R2 = 0.8; p < 0.001). 
3.3. Test modifications 
We re-tested several samples with inconclusive results (A) using 
washed platelets rather than PRP, (B) using platelets of a second donor, 
and (C) filtrating the patient’s serum to explore the potential effects of 
test modifications on the diagnostic performance. No systematic 
improvement of the results was observed, and the diagnostic perfor-
mance was similar. 
4. Discussion 
In a cross-sectional diagnostic accuracy study, we included 103 
consecutive patients referred with suspected HIT to study the perfor-
mance of a rapid, flow cytometer-based functional assay for the diag-
nosis of HIT and explored sources of variability. Among 15 patients with 
confirmed HIT, HIT confirm was positive in 9 patients, resulting in a 
60% sensitivity. Of 88 HIT-negative patients, HIT confirm was negative 
in 83 patients, leading to 94% specificity. Test modifications did not 
result in improved performance. 
Table 1 
Baseline characteristics of the study cohort (n = 103). Clinical characteristics were collected by the hematology consultancy service, and a 4Ts score was rated. HIT was 
defined as a positive heparin-induced platelet activation test (HIPA). Abbreviations: HIT, heparin-induced thrombocytopenia; IQR, interquartile range; OD, optical 
density; ELISA, enzyme-linked immunosorbent assay.   
HIT positive 
n = 15 (14.6%) 
HIT negative 
n = 88 (85.4%) 
All patients 
n = 103 (100%) 
Age in years, median (IQR) 73 (62, 77) 69 (59, 76) 69 (60, 76) 
Sex, numbers (%)    
Male 60 (58.3) 64 (62.1) 63 (61.2) 
Female 40 (38.7) 36 (37.9) 37 (38.8) 
4T’s score, median (IQR) 5 (3.5, 6.0) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 
IgG-specific GTI ELISA, median OD (IQR) 3.0 (2.1, 3.3) 0.2 (0.15, 0.4) 0.27 (0.15, 0.60) 
HemosIL®Acustar (IgG), median U/mL (IQR) 15.3 (2.3, 38.8) 0.0 (0.0, 0.0) 0.0 (0.0, 0.0)  
Fig. 2. Diagnostic accuracy of a functional, flow cytometer-based assay for the diagnosis of heparin-induced thrombocytopenia (HIT Confirm). (A) Distribution of 
test results (HEPLA%, percentage of CD62P positive events) according to the presence of HIT. Cut-offs are shown as dashed lines. (B) Classification table of HIT 
confirm according to the presence of HIT. The sensitivity was 60.0% (95% confidence interval 32.3, 83.7) and specificity was 94.3% (95% CI 87.2, 98.1). HIT was 
defined as a positive heparin-induced platelet activation test (HIPA). 
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Even though some differences exist, our results are essentially in line 
with previous publications. Althaus and colleagues studied 390 sera and 
determined the diagnostic accuracy regarding the HIPA test [16]. 
Sensitivity was 70%, and specificity was 75%. The most probable 
explanation for the higher sensitivity is that a different analyzer was 
used in Althaus’s study; all other analytical details were similar. These 
observations question the reproducibility of measurements among lab-
oratories. Vayne and colleagues conducted an artificial experiment 
using 5B9 monoclonal IgG antibodies mimicking human HIT antibodies 
and utilizing serum from 20 healthy volunteers and found a sensitivity of 
83% [10]. Tardy and colleagues analyzed 228 patients and determined 
the diagnostic accuracy with regard to expert opinion, and found a 
sensitivity of 83% [18]. 
The strength of our study is that HIT confirm was conducted in (1) 
consecutive patients referred for suspected HIT ensuring a representa-
tive study cohort, (2) the patients are well characterized, (3) an estab-
lished and objective reference standard was used in all patients, and (4) 
several test modifications were applied in order to explore sources of 
variability. As a limitation, the number of patients was limited, resulting 
in a restricted precision of the estimates. However, we do not believe 
that this might have influenced the results because they are similar to 
previous studies [10,16,18]. 
Several studies in different settings and using various study designs 
have assessed the diagnostic accuracy of the flow cytometer-based Emo- 
Test HIT Confirm for the diagnosis of HIT. Consistently, the sensitivity 
was limited (70%–83%). Considering that every fourth patient with HIT 
would be missed, this test is not feasible for clinical practice imple-
mentation. Of note, the sensitivity of high-quality immunoassays, some 
of which are available in a 24/7 service, is well above 95% [7]. Besides, 
we tested the effects of various test modifications, as suggested by others 
[16]. However, neither the use of a second, independent donor, nor 
washing of platelets, or filtration did improve the results. In contrast, our 
study suggests a high specificity (which was not observed in the study of 
Althaus et al.,). Thus, HIT confirm can be applied to verify HIT for sci-
entific purposes. 
5. Conclusions 
In the present cross-sectional diagnostic accuracy study, including 
103 consecutive patients referred with suspected HIT, the sensitivity of 
the rapid cytometer-based assay HIT confirm was inferior compared to 
the current reference standard. This finding confirms previous studies 
suggesting that HIT confirm is not able to rule-out HIT in clinical 
practice. Several test modifications did not improve test performance. 
Other rapid functional assays are needed to improve diagnostic pro-
cedures in clinical practice. 
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